Skip to main content
Top
Published in: Diabetology International 2/2012

01-06-2012 | Original article

Glycemic control and bone metabolism in postmenopausal women with type 2 diabetes mellitus

Authors: Takashi Terano, Sawako Suzuki, Tomohiko Yoshida, Hidekazu Nagano, Naoko Hashimoto, Takafumi Mayama, Hisashi Koide, Keiko Suyama, Tomoaki Tanaka, Kyohei Yamamoto, Ichiro Tatsuno

Published in: Diabetology International | Issue 2/2012

Login to get access

Abstract

Objective

Diabetes mellitus type 2 (T2DM) has accumulated attention as a fracture risk in osteoporosis. In the present study, we investigated the effect of glycemic level, its control, and its treatment on bone mineral density (BMD) and bone metabolism focusing on Japanese postmenopausal women with T2DM.

Methods

BMD was determined by dual-energy X-ray absorptiometry to calculate T score and Z score at the lumbar spine at L2–4. Bone metabolic markers such as serum type 1 collagen cross-linked N-telopeptides (sNTX), a marker of bone resorption, and serum bone-specific alkaline phosphatase (BAP), a marker of bone formation, were measured.

Results

We enrolled 55 Japanese postmenopausal women with T2DM [initial age 63.5 ± 7.7 years, BMI 22.8 ± 3.5 kg/m2, hemoglobin A1c (HbA1c) 7.53 ± 1.94% (HbA1c Japanese Diabetes Society; JDS) 7.26 ± 1.68%], L2–4 BMD 0.927 ± 0.169 g/cm2, T score −0.738 ± 1.527; Z score 0.945 ± 1.272]. There were no significant differences on L2–4 BMD, T score, Z score, or bone metabolic markers among three treatment groups regarding diet, orally administered medication, and insulin. In the analysis of correlation coefficients, HbA1c significantly correlated with sNTX (r = 0.363, p = 0.008), and the significant, but weak, correlation was observed between HbA1c and Z score (r = 0.306, p = 0.026). In patients newly treated with intensive insulin therapy (n = 5), glycemic control significantly suppressed sNTX after 3 months (p < 0.05).

Conclusions

The control of glycemic level might be correlated with osteoclast function in terms of bone resorption marker, which might be linked with fracture risk in postmenopausal women with T2DM.
Literature
1.
go back to reference Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Annu Rev Public Health. 2005;26:115–40.PubMedCrossRef Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Annu Rev Public Health. 2005;26:115–40.PubMedCrossRef
2.
go back to reference Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318–25.PubMedCrossRef Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318–25.PubMedCrossRef
4.
go back to reference Szmuilowicz ED, Stuenkel CA, Seely EW. Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol. 2009;5:553–8.PubMedCrossRef Szmuilowicz ED, Stuenkel CA, Seely EW. Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol. 2009;5:553–8.PubMedCrossRef
5.
go back to reference Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22:1317–28.PubMedCrossRef Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22:1317–28.PubMedCrossRef
6.
go back to reference Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91:3404–10.PubMedCrossRef Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91:3404–10.PubMedCrossRef
7.
go back to reference Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Zmuda JM, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res. 2004;19:1084–91.PubMedCrossRef Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Zmuda JM, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res. 2004;19:1084–91.PubMedCrossRef
8.
go back to reference Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care. 2007;30:835–41.PubMedCrossRef Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care. 2007;30:835–41.PubMedCrossRef
9.
go back to reference Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18:427–44.PubMedCrossRef Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18:427–44.PubMedCrossRef
10.
go back to reference Dobnig H, Piswanger-Solkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006;91:3355–63.PubMedCrossRef Dobnig H, Piswanger-Solkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006;91:3355–63.PubMedCrossRef
11.
go back to reference Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005;16:1506–12.PubMedCrossRef Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005;16:1506–12.PubMedCrossRef
12.
go back to reference Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:45–9.PubMedCrossRef Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:45–9.PubMedCrossRef
13.
go back to reference Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int. 2009;85:228–34.PubMedCrossRef Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int. 2009;85:228–34.PubMedCrossRef
14.
go back to reference Nagasaka S, Murakami T, Uchikawa T, Ishikawa SE, Saito T. Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with non-insulin-dependent diabetes mellitus. Endocr J. 1995;42:377–83.PubMedCrossRef Nagasaka S, Murakami T, Uchikawa T, Ishikawa SE, Saito T. Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with non-insulin-dependent diabetes mellitus. Endocr J. 1995;42:377–83.PubMedCrossRef
15.
go back to reference Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, Hata K, Fukumoto S, Matsumoto T. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab. 1997;82:2915–20.PubMedCrossRef Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, Hata K, Fukumoto S, Matsumoto T. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab. 1997;82:2915–20.PubMedCrossRef
16.
go back to reference Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int. 1998;63:107–11.PubMedCrossRef Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int. 1998;63:107–11.PubMedCrossRef
17.
go back to reference Sayinalp S, Gedik O, Koray Z. Increasing serum osteocalcin after glycemic control in diabetic men. Calcif Tissue Int. 1995;57:422–5.PubMedCrossRef Sayinalp S, Gedik O, Koray Z. Increasing serum osteocalcin after glycemic control in diabetic men. Calcif Tissue Int. 1995;57:422–5.PubMedCrossRef
18.
go back to reference Shu A, Yin MT, Stein E, Cremers S, Dworakowski E, Ives R, Rubin MR. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2011 [Epub ahead of print] Shu A, Yin MT, Stein E, Cremers S, Dworakowski E, Ives R, Rubin MR. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2011 [Epub ahead of print]
19.
go back to reference Anonymous WHO Study Group. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Geneva: WHO; 1994. Anonymous WHO Study Group. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Geneva: WHO; 1994.
20.
go back to reference Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetol Int. 2010;1:2–20.CrossRef Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetol Int. 2010;1:2–20.CrossRef
21.
go back to reference Thomas DM, Hards DK, Rogers SD, Ng KW, Best JD. Insulin receptor expression in bone. J Bone Miner Res. 1996;11:1312–20.PubMedCrossRef Thomas DM, Hards DK, Rogers SD, Ng KW, Best JD. Insulin receptor expression in bone. J Bone Miner Res. 1996;11:1312–20.PubMedCrossRef
22.
go back to reference Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008;23:1334–42.PubMedCrossRef Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008;23:1334–42.PubMedCrossRef
23.
go back to reference Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–9.PubMedCrossRef Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–9.PubMedCrossRef
24.
go back to reference Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292–9.PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292–9.PubMedCrossRef
25.
go back to reference Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab. 2010;28:554–60.PubMedCrossRef Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab. 2010;28:554–60.PubMedCrossRef
26.
go back to reference Hosoda H, Fukui M, Nakayama I, Asano M, Kadono M, Hasegawa G, Yoshikawa T, Nakamura N. Bone mass and bone resorption in postmenopausal women with type 2 diabetes mellitus. Metabolism. 2008;57:940–5.PubMedCrossRef Hosoda H, Fukui M, Nakayama I, Asano M, Kadono M, Hasegawa G, Yoshikawa T, Nakamura N. Bone mass and bone resorption in postmenopausal women with type 2 diabetes mellitus. Metabolism. 2008;57:940–5.PubMedCrossRef
27.
go back to reference Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006;99:411–24.PubMedCrossRef Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006;99:411–24.PubMedCrossRef
28.
go back to reference Capoglu I, Ozkan A, Ozkan B, Umudum Z. Bone turnover markers in patients with type 2 diabetes and their correlation with glycosylated haemoglobin levels. J Int Med Res. 2008;36:1392–8.PubMed Capoglu I, Ozkan A, Ozkan B, Umudum Z. Bone turnover markers in patients with type 2 diabetes and their correlation with glycosylated haemoglobin levels. J Int Med Res. 2008;36:1392–8.PubMed
29.
go back to reference Danielson KK, Elliott ME, LeCaire T, Binkley N, Palta M. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int. 2009;20:923–33.PubMedCrossRef Danielson KK, Elliott ME, LeCaire T, Binkley N, Palta M. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int. 2009;20:923–33.PubMedCrossRef
30.
go back to reference Williams JP, Blair HC, McDonald JM, McKenna MA, Jordan SE, Williford J, Hardy RW. Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun. 1997;235:646–51.PubMedCrossRef Williams JP, Blair HC, McDonald JM, McKenna MA, Jordan SE, Williford J, Hardy RW. Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun. 1997;235:646–51.PubMedCrossRef
31.
go back to reference Chesnut CH 3rd, Rosen CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res. 2001;16:2163–72.PubMedCrossRef Chesnut CH 3rd, Rosen CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res. 2001;16:2163–72.PubMedCrossRef
33.
go back to reference Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531–8.PubMedCrossRef Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531–8.PubMedCrossRef
Metadata
Title
Glycemic control and bone metabolism in postmenopausal women with type 2 diabetes mellitus
Authors
Takashi Terano
Sawako Suzuki
Tomohiko Yoshida
Hidekazu Nagano
Naoko Hashimoto
Takafumi Mayama
Hisashi Koide
Keiko Suyama
Tomoaki Tanaka
Kyohei Yamamoto
Ichiro Tatsuno
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Diabetology International / Issue 2/2012
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-011-0058-3

Other articles of this Issue 2/2012

Diabetology International 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine